Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

First International Summit on Interventional Pharmacoeconomics

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

Leonard B. Saltz, MD, on Interventional Pharmacoeconomics: A Pathway to Better Cancer Care

Leonard B. Saltz, MD, of Memorial Sloan Kettering Cancer Center, discusses interventional pharmacoeconomics as an important tool that can offer patients with cancer more efficacious and cost-effective care. Pharmacoeconomics may help reduce the high costs of cancer therapy, with evidence-based reductions in doses that maintain effective treatment.

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Welcome and Introduction to Vi3C

David A. Hyman, MD, JD, on Inclusive Shared Savings

Oct

Today In Oncology

Hypofractionated vs Conventionally Fractionated Postmastectomy Radiation FABREC Trial

Stereotactic Radiotherapy for Patients With Primary RCC Unsuitable for Surgery FASTRACK II

SBRT vs Standard Radiotherapy for Localized Prostate Cancer: 5-Year Analysis of PACE B

Relapsed or Refractory Multiple Myeloma Mezigdomide Plus Dexamethasone

Allogeneic HCT Outcomes in Patients With MDS and High-Risk Genetics

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Related Videos